Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EBT (2016 - 2025)

Historic EBT for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $239.4 million.

  • Neurocrine Biosciences' EBT rose 4723.25% to $239.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $705.4 million, marking a year-over-year increase of 4514.4%. This contributed to the annual value of $705.4 million for FY2025, which is 4514.4% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported EBT of $239.4 million as of Q4 2025, which was up 4723.25% from $291.8 million recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' EBT ranged from a high of $291.8 million in Q3 2025 and a low of -$103.3 million during Q1 2023
  • For the 4-year period, Neurocrine Biosciences' EBT averaged around $109.2 million, with its median value being $115.6 million (2023).
  • As far as peak fluctuations go, Neurocrine Biosciences' EBT soared by 15341.51% in 2021, and later crashed by 5739.13% in 2025.
  • Over the past 4 years, Neurocrine Biosciences' EBT (Quarter) stood at $30.5 million in 2021, then soared by 549.84% to $198.2 million in 2023, then decreased by 17.96% to $162.6 million in 2024, then skyrocketed by 47.23% to $239.4 million in 2025.
  • Its EBT stands at $239.4 million for Q4 2025, versus $291.8 million for Q3 2025 and $159.5 million for Q2 2025.